Objective: Atrial fibrillation (AF) is the most common cardiac rhythm disorder with the associated risks of stroke and mortality. The usefulness of platelet to lymphocyte ratio (PLR), a recently described inflammatory marker, in predicting adverse cardiovascular events has been demonstrated in several studies. In the current study, we investigated the role of PLR in predicting recurrence after successful electrical cardioversion (ECV) in patients with non-valvular persistent AF.
pericarditis, myocarditis, or cardiac surgery suggest that inflammation may be particularly important for initiation of AF among cardiac rhythm disturbances (Bruins et al., 1997; Chung et al., 2001; Spodick, 1976) .
Studies with inflammatory markers such as C-reactive protein (CRP), interleukin 6 (IL-6), high-sensitivity CRP (hs-CRP) have provided supportive evidence for the link between AF and inflammation (Psychari et al., 2005; Sata et al., 2004; Watanabe, Arakawa, Uchiyama, Kodama, & Hishida, 2006) . Although CRP is the most commonly used marker of inflammation, platelet to lymphocyte ratio (PLR) has also recently been shown to be a useful marker of inflammation in certain conditions (Thaulow, Erikssen, Sandvik, Stormorken, & Cohn, 1991) .
Platelet to lymphocyte ratio can be readily calculated using routine complete blood counts (CBCs) and represents a novel prognostic marker in cardiovascular diseases (Iijima et al., 2007; Nikolsky et al., 2007; Zouridakis, Garcia-Moll, & Kaski, 2000) . While increased platelet counts reflect more marked inflammation, low lymphocyte counts suggest poor general health and physiological stress. PLR is a stronger indicator combining these two independent parameters (Gensini, 1983) .
Several studies have established the role of PLR as a systemic inflammatory marker (Balta, Demırkol, & Kucuk, 2013) . Again, in a recent study increased PLR was found to be associated with the risk of developing AF following cardiac surgery (Gungor et al., 2017) . On the other hand, to our knowledge, the predictive value of PLR for AF recurrence after cardioversion has never been studied before. Thus, in this study, we aimed at assessing the relationship between PLR and AF recurrences after successful cardioversion.
| ME THODS

| Study design and population
The study design is a prospective cohort study. A total of 287 nonvalvular persistent AF patients over 18 years of age with a minimum follow-up duration of 6 months after successful elective ECV with restoration to sinus rhythm (SR) between July 2014 and June 2018 were prospectively included. Exclusion criteria were as follows: presence of thrombus in the left atrium and appendix, having undergone ablation for AF, left atrial (LA) diameter >50 mm, use of class I or III antiarrhythmic within the past 6 months, a diagnosis of paroxysmal or permanent AF, presence of permanent cardiac pacemaker, acute coronary syndrome, congenital cardiac disease, NYHA class IV heart failure, active inflammatory or infectious disease, moderate to severe kidney failure, severe hepatic failure, thyroid dysfunction, malignancy, alcohol use, and pregnancy. The study protocol was approved by the local ethics committee. Written consent and oral informed consent were obtained from each patient after information on AF and ECV as well as the need for the procedure was provided.
| Clinical data and echocardiography
Age, gender, weight, height, body mass index (BMI, kg/m 2 ), and cardiac apex beat per minute were recorded for each patient.
History of congestive heart failure, hypertension, diabetes, thromboembolic events, thyroid conditions, smoking, and duration of AF were determined, followed by the estimation of CHA2DS2-VASc 
| Cardioversion
| Discharge and follow-up
Patients with restoration of the sinus rhythm after ECV received anticoagulation (warfarin) for at least 4 weeks to achieve an INR.
Patients who were using oral anticoagulant treatment prior to ECV continued to present anticoagulant treatment after the procedure.
Also, subjects with a failure to restore SR after unsuccessful ECV received oral anticoagulant therapy at discharge if CHA2DS2-VASc was ≥1. Four weeks after ECV procedure, antiarrhythmic treatment was continued with oral amiodarone. In order to detect possible recurrences, patients were instructed to seek immediate medical attention if they felt palpitations or irregular heartbeats. During the follow-up, patients were examined on four separate occasions (weeks 2 and 4, and months 3 and 6), unless they had palpitations. In subjects with palpitations, in addition to periodic follow-up controls, a 12-lead electrocardiography followed by 3-day Holter ECG monitoring was performed. During the follow-up period, identification of a paroxysmal AF episode lasting more than 30 s in the 12-lead ECG or 3-day Holter recordings was considered to indicate recurrence (Van Gelder et al., 2002) . After 6 months of follow-up, no patients had embolic or hemorrhagic complications. Eleven patients were lost to follow-up and were therefore excluded from the study. Thus, a total of 276 patients completed the study.
| Endpoints
The primary outcome was the proportion of patients with sustained SR after ECV during 6 months of follow-up. Arrhythmia lasting for more than 30 s in 12-lead ECG or Holter recordings during the follow-up period was considered as the primary endpoint.
| Statistical assessments
The data analysis was conducted using SPSS (version 20.0, SPSS 
| RE SULTS
After 6 months of follow-up, no patients had embolic or hemorrhagic complications. A total of 11 patients were lost to follow-up and were therefore excluded from the study. Thus, a total of 276 patients completed the study.
About 276 patients who had restoration of SR following elective ECV were included, and 108 patients had recurrence of AF during 6 months of follow-up corresponding to a recurrence rate of 39%.
Patients were divided into two groups at the completion of the study period as those who sustained SR and those who continued to have AF. Tables 1 and 2 show the clinical and laboratory characteristics of the patients, respectively.
There were no significant differences between the groups with regard to duration of AF, gender, heart rate, smoking status, history of stroke, and biochemical parameters other than the platelet count.
However, the two groups were significantly different in terms of The results of the multiple regression analysis are shown in Table 3 . Accordingly, PLR was found to be a risk factor associated with long-term AF recurrence after successful ECV (OR: 3,029 [95% CI 1,013%-9,055], p = 0.01). Furthermore, in a receiver operating characteristic analysis using a cutoff value of 147, the sensitivity and specificity of PLR in predicting AF recurrence were 83.3%
and 84.5%, respectively (area under ROC curve = 0.645, p < 0.001; Figure 1 ). 
| D ISCUSS I ON
Our results have shown that PLR is a risk factor associated with longterm AF recurrence after successful ECV in non-valvular persistent AF patients. 
TA B L E 3 Univariate and multivariate logistic regression analyses
during 5 years of follow-up. In several studies investigating the success rates with pharmacological or DC cardioversion and maintenance of sinus rhythm, an adverse effect due to an increase in inflammatory markers such as IL-6, IL-2, and hs-CRP has been shown to occur (Fujiki, Sakamoto, Nishida, Mizumaki, & Inoue, 2007; Malouf et al., 2005; Ozaydin et al., 2011; Rizos et al., 2007) . In a study by Celebi et al. (2011, elevated hs-CRP levels were found to be associated with AF recurrence during 12 months of follow-up after ECV, suggesting that an association between AF and inflammation exists based on the electrical and structural remodeling (Nakamura et al., 2003) .
PLR is calculated as the ratio between the number of platelets and lymphocytes, and represents a new reproducible and practical biological marker of systemic inflammation. It combines the prognostic value of the number of both platelets and lymphocytes in cardiovascular disorders. Number of lymphocytes is a rational early marker of physiological and systemic inflammation.
Reduced numbers of lymphocytes in PLR ratio are indicative of physiological stress and poor general health, and provide more detailed information as compared to leukocyte numbers alone (Hotchkiss & Karl, 2003; Onsrud & Thorsby, 1981) . Platelets release pro-inflammatory mediators such as chemokines and cytokines (Demirtas et al., 2014) . Adults with elevated numbers of platelets also carry an increased risk of thrombotic complications.
Circulatory platelets may contribute to the formation of atheromatous plaques and may trigger complications (Thaulow et al., 1991) .
Previously, high circulatory platelets and low lymphocytes have been proposed to be indicative of worse cardiovascular risk (Iijima et al., 2007; Nikolsky et al., 2007; Ommen et al., 1998; Thaulow et al., 1991; Thomson et al., 1995; Zouridakis et al., 2000) .
Platelet distribution width, erythrocyte distribution width, and mean platelet volume are among the components of CBC, which may serve as inflammatory markers, when one considers previous studies that have clearly indicated the presence of a relationship between these parameters and various cardiovascular conditions. On the other hand, since PLR is a ratio, it is relatively more stable than the above-mentioned parameters that may be influenced by a number of factors (e.g., dehydration, excessive water intake, or treatment with blood products). Thus, from a practical viewpoint, PLR potentially represents a superior measure than other CBC parameters such as the simple leukocyte or platelet count.
In a study by Gary et al., (2013, PLR was found to be correlated with fibrinogen, which may impair the blood viscosity and thus tissue oxygen supply; also, these authors reported that higher platelet volumes may alter the blood viscosity and worsen inflammation. Amiodarone is an effective multichannel blocker, which reduces ventricular rate and is safe in patients with heart failure (Roy et al., 2008; Singh, Tang, Reda, & Singh, 2009) . Pretreatment with amiodarone can increase the effectiveness of electrical cardioversion (Channer et al., 2004; Singh et al., 2009 Nabauer et al., 2009 ). For these reasons, we chose amiodarone as a antiarrhythmic agents in our study. In addition, patients with severe heart failure or significant valvular heart disease (aortic stenosis) were present in the study population, so we were unable to use alternative antiarrhythmic agents to amiodarone. We used short-term antiarrhythmic treatment for 1 week before and 4 weeks after ECV procedure.
Many factors may affect the maintenance and recurrence of sinus rhythm following successful ECV, and a better understanding of such factors may help develop better therapeutic strategies.
Number of studies showing an association between AF recurrence
The receiver operating characteristic (ROC) curve analysis of platelet-to-lymphocyte ratio for predicting atrial fibrillation recurrence and different novel indices such as echocardiographically determined left atrial volume index and atrial emptying fraction, and biomarkers including cardiotroponin-1 and N-terminal pro-brain natriuretic peptide (NT-proBNP) are increasing (Altun et al., 2015; Andersson, Rosenqvist, Tornvall, & Boman, 2015; Luong et al., 2016; Toufan, Kazemi, & Molazadeh, 2017) . These predictors may serve as a valuable tool when determining the rhythm control in clinical practice and when planning ECV; however, less expensive and more practical measures are required to predict recurrences.
In this regard, PLR is a practical and widely utilized parameter requiring no additional costs that may be used for risk estimations prior to ECV.
| Study limitations
The limitations of our study include the short duration of followup, small sample size, and use of ECG for detection of recurrences.
Routine use of 72-hr holter monitoring could have provided more accurate results with regard to AF screening. However, this could not be routinely performed due to cost-related issues, potentially leading to overlooking of paroxysmal AF recurrences in some asymptomatic patients. Absence of measurement of other established inflammatory markers such as CRP, interleukin-6, and tumor necrosis factor may also be considered a potential limitation. Also, our results do not provide evidence for a causal relationship between PLR and AF.
Although we identified a significant correlation, further prospective studies with larger sample size are warranted to better delineate this relationship. Despite these limitations, to the best of our knowledge, this is one of the first studies to examine the association between PLR at baseline and AF recurrence after ECV.
| CON CLUS ION
Our results have shown that PLR is an independent parameter for predicting recurrence of AF after successful ECV in non-valvular persistent AF patients. PLR is an inexpensive and practical param- 
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